Pharmacology Discovery Services has over 50 years of experience in developing and conducting studies with a diverse set of in vivo models for inflammatory diseases. These models range from basic models of immune modulation, restoration, suppression, and stimulation to specific models of inflammation-induced organ damage.

Our ability to deliver multi-faceted outcome studies means that you will receive the data that is most appropriate for your drug discovery program. All experimental models are tested in a dose-dependent manner with approved benchmark positive controls. We routinely measure relevant biomarkers (e.g., cytokines) and physiologic outcomes, like airway hyperresponsiveness and swelling. We can also provide more complex behavioral outcome measures such as scratching, mechanical allodynia, or histopathology. To meet the needs of your specific Inflammation/Allergy drug discovery project, we also have the flexibility and expertise to develop custom in vivo models.

Speak with
an expert

Download Our
Inflammation Brochure

*Other auto-immune disease models include Inflammatory Bowel Disease (found under Digestive System) and Psoriasis (found under Dermal Inflammation).

Publications

• Probing the Role of Melanocortin Type 1 Receptor Agonists in Diverse Immunological Diseases. Spana C et al. Front. Pharmacol. 2019 Jan;9:1535. https://doi.org/10.3389/fphar.2018.01535
• Design and Synthesis of Enantiomerically Pure Decahydroquinoxalines as Potent and Selective κ-Opioid Receptor Agonists with Anti-Inflammatory Activity in Vivo. Soeberdt M et al. J. Med. Chem. 2017 Mar;60(6):2526-2551. https://doi.org/10.1021/acs.jmedchem.6b01868
• A human and animal model-based approach to investigating the anti-inflammatory profile and potential of the 5-HT2B receptor antagonist AM1030. Palmgvist N et al. J Inflamm. 2016 Jun;13:20. https://doi.org/10.1186/s12950-016-0127-2
• G protein-coupled bile acid receptor 1 stimulation mediates arterial vasodilation through a K(Ca)1.1 (BK(Ca))-dependent mechanism. Fryer RM et al. J Pharmacol Exp Ther. 2014 Mar;348(3):421-31. https://doi.org/10.1124/jpet.113.210005